Januvia
- All
- News
-
Evaluating Legal Options Over Diabetes Drug Setback: Glenmark
Drug firm Glenmark Pharmaceuticals on Thursday said it is evaluating legal options after the Delhi High Court restrained it from manufacturing and selling generic version of Merck Sharp and Dohme's anti-diabetes medicines Januvia and Janumet.
-
Court Bars Glenmark from Selling Copies of Merck Diabetes Drugs: Report
The court has, however, allowed Glenmark to continue to sell existing inventory, the sources said.
-
Drug patent row: High Court seeks Glenmark's response by May 22
The American drug major is involved in a patent row with Glenmark which has recently come out with the two medicines in alleged violation of intellectual property rights (IPR) used in its drugs Januvia and Janumet.
-
Patent row: Drug firm Merck files appeal against interim order
US pharmaceutical major Merck Sharp and Dohme (MSD) has filed an appeal before the Delhi High Court challenging its single bench order refusing to grant interim relief to it on a patent row against Indian firm Glenmark Pharmaceuticals.
-
Patent row: High Court refuses interim relief to US drug firm Merck
Justice Rajiv Sahai Endlaw dismissed the interim application of the multinational pharma major that the Mumbai-based firm be restrained from manufacturing and selling the anti-diabetes medicines on the grounds that the salt used in the drugs were not of generic nature.
-
Evaluating Legal Options Over Diabetes Drug Setback: Glenmark
Drug firm Glenmark Pharmaceuticals on Thursday said it is evaluating legal options after the Delhi High Court restrained it from manufacturing and selling generic version of Merck Sharp and Dohme's anti-diabetes medicines Januvia and Janumet.
-
Court Bars Glenmark from Selling Copies of Merck Diabetes Drugs: Report
The court has, however, allowed Glenmark to continue to sell existing inventory, the sources said.
-
Drug patent row: High Court seeks Glenmark's response by May 22
The American drug major is involved in a patent row with Glenmark which has recently come out with the two medicines in alleged violation of intellectual property rights (IPR) used in its drugs Januvia and Janumet.
-
Patent row: Drug firm Merck files appeal against interim order
US pharmaceutical major Merck Sharp and Dohme (MSD) has filed an appeal before the Delhi High Court challenging its single bench order refusing to grant interim relief to it on a patent row against Indian firm Glenmark Pharmaceuticals.
-
Patent row: High Court refuses interim relief to US drug firm Merck
Justice Rajiv Sahai Endlaw dismissed the interim application of the multinational pharma major that the Mumbai-based firm be restrained from manufacturing and selling the anti-diabetes medicines on the grounds that the salt used in the drugs were not of generic nature.
